State Street Corp Revance Therapeutics, Inc. Transaction History

State Street Corp

  • $2.41 Trillion
  • Q3 2024

A detailed history of State Street Corp transactions in Revance Therapeutics, Inc. stock. As of the latest transaction made, State Street Corp holds 2,433,963 shares of RVNC stock, worth $6.26 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,433,963
Previous 2,283,640 6.58%
Holding current value
$6.26 Million
Previous $5.87 Million 6.6%
% of portfolio
0.0%
Previous 0.0%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024
BUY
$2.57 - $2.57 $386,330 - $386,330
150,323 Added 6.58%
2,433,963 $6.26 Million
Q2 2024

Aug 14, 2024
SELL
$2.34 - $4.73 $175,820 - $355,398
-75,137 Reduced 3.19%
2,283,640 $5.87 Million
Q1 2024

May 15, 2024
SELL
$4.65 - $9.31 $757,559 - $1.52 Million
-162,916 Reduced 6.46%
2,358,777 $11.6 Million
Q4 2023

Feb 14, 2024
BUY
$5.81 - $11.2 $1.1 Million - $2.11 Million
188,585 Added 8.08%
2,521,693 $22.2 Million
Q3 2023

Nov 14, 2023
BUY
$11.47 - $25.07 $3.24 Million - $7.08 Million
282,326 Added 13.77%
2,333,108 $26.8 Million
Q2 2023

Aug 14, 2023
BUY
$24.7 - $37.61 $2.54 Million - $3.87 Million
103,019 Added 5.29%
2,050,782 $51.9 Million
Q1 2023

May 15, 2023
SELL
$18.36 - $35.27 $1.87 Million - $3.59 Million
-101,832 Reduced 4.97%
1,947,763 $62.7 Million
Q4 2022

Feb 14, 2023
BUY
$18.32 - $30.66 $7.94 Million - $13.3 Million
433,142 Added 26.8%
2,049,595 $37.8 Million
Q3 2022

Nov 15, 2022
SELL
$14.33 - $28.47 $2.34 Million - $4.65 Million
-163,340 Reduced 9.18%
1,616,453 $43.6 Million
Q2 2022

Aug 15, 2022
BUY
$11.52 - $20.4 $2.75 Million - $4.86 Million
238,356 Added 15.46%
1,779,793 $24.6 Million
Q1 2022

May 16, 2022
SELL
$12.36 - $20.31 $314,055 - $516,056
-25,409 Reduced 1.62%
1,541,437 $30.1 Million
Q4 2021

Feb 14, 2022
BUY
$12.46 - $27.87 $735,239 - $1.64 Million
59,008 Added 3.91%
1,566,846 $25.6 Million
Q3 2021

Nov 15, 2021
BUY
$25.78 - $33.21 $1.84 Million - $2.37 Million
71,394 Added 4.97%
1,507,838 $42 Million
Q2 2021

Aug 16, 2021
BUY
$26.8 - $31.84 $2.29 Million - $2.72 Million
85,278 Added 6.31%
1,436,444 $42.6 Million
Q1 2021

May 17, 2021
SELL
$24.03 - $29.97 $2.86 Million - $3.57 Million
-119,110 Reduced 8.1%
1,351,166 $37.8 Million
Q4 2020

Feb 16, 2021
BUY
$23.41 - $28.34 $3.04 Million - $3.68 Million
129,870 Added 9.69%
1,470,276 $41.7 Million
Q3 2020

Nov 10, 2020
SELL
$23.23 - $34.3 $224,727 - $331,818
-9,674 Reduced 0.72%
1,340,406 $33.7 Million
Q2 2020

Aug 14, 2020
BUY
$12.6 - $26.55 $2.41 Million - $5.07 Million
191,025 Added 16.48%
1,350,080 $33 Million
Q1 2020

May 11, 2020
BUY
$12.46 - $27.81 $14.4 Million - $32.2 Million
1,159,055 New
1,159,055 $17.2 Million

Others Institutions Holding RVNC

# of Institutions
234
Shares Held
82.8M
Call Options Held
680K
Put Options Held
896K
View Full List

About Revance Therapeutics, Inc.

RVNC Quotes by TradingView
  • Ticker RVNC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 82,305,696
  • Market Cap $212M
  • Description
  • Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...
More about RVNC
Track This Portfolio

Track State Street Corp Portfolio

Follow State Street Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email